The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
← catalyst calendarNCT06975865 · readout in 338 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
192estimated
Sites
53
Countries
Belgium, Brazil, France +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-12 | actual | When the study began enrolling |
| Primary completion | 2027-07-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Interventions
- Drug: Rilzabrutinib — also filed as SAR444671
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of clinical VOC
measured At Week 52
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed